<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04269304</url>
  </required_header>
  <id_info>
    <org_study_id>IRAS - 256931</org_study_id>
    <secondary_id>47270</secondary_id>
    <secondary_id>210572/Z/18/Z</secondary_id>
    <nct_id>NCT04269304</nct_id>
  </id_info>
  <brief_title>Deciphering AMD by Deep Phenotyping and Machine Learning- Prospective Study - PINNACLE</brief_title>
  <acronym>PINNACLE</acronym>
  <official_title>Deciphering AMD by Deep Phenotyping and Machine Learning- Prospective Study - PINNACLE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southampton</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Imperial College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Basel</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Michigan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Southampton</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We will conduct a prospective non-interventional study including 400 early AMD patients (=600&#xD;
      untreated early AMD eyes, including both unilateral (AREDS IV) and bilateral (≥AREDS II))&#xD;
      over a minimum of 1 year to specifically investigate the morphological sequence of events&#xD;
      preceding the conversion towards late AMD. All patients will be followed by OCT imaging every&#xD;
      4 months to detect the earliest focal sites of disease progression. As soon as focal areas of&#xD;
      change are observed by the VRC, a targeted follow-up schedule will be triggered to&#xD;
      investigate the events at that area of change in a targeted manner.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We will recruit patients with 1) intermediate AMD in one eye and advanced AMD in the&#xD;
      non-study eye or 2) patients with bilateral intermediate AMD (where both eyes will be&#xD;
      included). As some participants are symptomless at the stage of intermediate AMD, we will&#xD;
      recruit from hospital databases including imaging databases and ophthalmology and optometry&#xD;
      practices and engagement with Patient Societies e.g. the Macular Society and patient public&#xD;
      involvement meetings.&#xD;
&#xD;
      There will be four clinical sites performing detailed assessments on 50 patients each and, to&#xD;
      increase sample size, an additional eight referral sites in the UK who will each enrol and&#xD;
      follow 25 study patients by SD-OCT every 4 months. The acquired images from these referral&#xD;
      sites will be sent to the Vienna Reading Centre for morphological identification of focal&#xD;
      events. If a focal event is detected, participants will then be referred for a detailed,&#xD;
      targeted assessment at either the University of Southampton or Moorfields Eye Hospital as&#xD;
      detailed below.&#xD;
&#xD;
      After consent, patients will undergo visual function tests (ETDRS visual acuity,&#xD;
      microperimetry) and multimodal imaging including fundus photographs, OCT scans, OCT&#xD;
      angiography, autofluorescence and adaptive optics imaging. The visual function tests will be&#xD;
      repeated annually and the multimodal imaging will be done at 4 monthly intervals for a&#xD;
      minimum of 1 year. Blood will be taken within the first year for DNA analysis.&#xD;
&#xD;
      200 patients (main cohort) will undergo dense retinal phenotyping at a minimum of 4 visits.&#xD;
&#xD;
      Medical and smoking history, genotype and body mass index will also be included in the&#xD;
      analysis as has been done previously. As well as structural tests, functional tests will be&#xD;
      performed at baseline and end of the study using both microperimetry (a type of visual field&#xD;
      test to create a &quot;retinal sensitivity map&quot; of the quantity of light perceived in specific&#xD;
      parts of the retina) to identify focal changes and low luminance visual acuity to assess&#xD;
      global changes. To increase sample size but make the study feasible an additional 200&#xD;
      patients at UK referral sites will undergo 4 monthly OCT and be referred to Southampton /&#xD;
      Moorfields for dense phenotyping only if a focal event is detected by OCT.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 28, 2019</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity / specificity of OCT and autofluorescence parameters.</measure>
    <time_frame>3 years</time_frame>
    <description>Identified by machine learning (ML) at predicting disease progression defined as focal conversion towards advanced AMD e.g. change in drusen volume, development of new geographic atrophy / choroidal neovascularisation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensitivity / specificity of novel imaging characteristics</measure>
    <time_frame>3 years</time_frame>
    <description>For example, AO-OCT, OCT-A, at predicting disease progression; ROC curves; time from development of imaging change to development of these end-points; structure-function correlation; structure-genotype correlation; predictive risk models.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Observational</arm_group_label>
    <description>Intermediate Age-Related Macular Degeneration Patients</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA for genotype analysis.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with 1) intermediate AMD in one eye and advanced AMD in the non-study eye or 2)&#xD;
        patients with bilateral intermediate AMD (where both eyes will be included).&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subjects ≥ 55 years with either intermediate AMD (as defined by Ferris et al PMID:&#xD;
             23332590) in both eyes, i.e. large drusen &gt; 125 um and/or any definite hyper- or&#xD;
             hypopigmentary abnormalities associated with medium or large drusen; or intermediate&#xD;
             AMD as defined above in one eye (study eye) and advanced AMD (geographic atrophy or&#xD;
             choroidal neovascularization secondary to AMD) in the other eye.&#xD;
&#xD;
          -  Subjects should have media clarity and pupillary dilation for adequate imaging and&#xD;
             functional tests.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Co-existent ocular disease, which might affect visual function or retinal morphology&#xD;
&#xD;
          -  Established glaucoma in either study eye or fellow eye with evidence of visual field&#xD;
             loss or retinal nerve fibre loss (ocular hypertension is not an exclusion criterion&#xD;
             unless associated with visual field loss or retinal nerve fibre loss in either eye).&#xD;
&#xD;
          -  Cataract sufficient to affect retinal imaging&#xD;
&#xD;
          -  Myopia &gt; minus 6 diopters or a history of myopia &gt; minus 6 diopters if patient has had&#xD;
             cataract / refractive surgery.&#xD;
&#xD;
          -  Major ocular surgery 3 months prior or anticipated within the next 6 months following&#xD;
             enrolment.&#xD;
&#xD;
          -  Taking drugs known to cause retinal toxicity such as hydroxychloroquine or tamoxifen&#xD;
&#xD;
          -  OCT evidence of geographic atrophy (or complete RPE and outer retinal atrophy (cRORA).&#xD;
             This is (1) a region of hypertransmission of at least 250 mm in diameter, (2) a zone&#xD;
             of attenuation or disruption of the RPE of at least 250 mm in diameter, (3) evidence&#xD;
             of overlying photoreceptor degeneration, and (4) absence of scrolled RPE or other&#xD;
             signs of an RPE tear.&#xD;
&#xD;
          -  OCT evidence of choroidal neovascularization e.g sub-retinal scar tissue, sub-retinal&#xD;
             fluid or intra-retinal fluid associated with a pigment epithelial detachment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew J Lotery, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southampton</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrew J Lotery, Prof</last_name>
    <phone>023 8120 5049</phone>
    <phone_ext>5049</phone_ext>
    <email>A.J.Lotery@soton.ac.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>PINNACLE email address Sutton, BSc</last_name>
    <phone>023 8120 5240</phone>
    <phone_ext>5240</phone_ext>
    <email>pinnacle@soton.ac.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Riedl</last_name>
      <phone>+43 (0)1 40400 79240</phone>
      <email>sophie.riedl@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Ursula Schmidt-Erfurth, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ghislaine L Traber, MD</last_name>
      <phone>+41 (0) 61 265 78 88</phone>
      <email>ghislaine.traber@usb.ch</email>
    </contact>
    <contact_backup>
      <last_name>Daniela Hauenstein</last_name>
      <phone>+41 61 265 87 18</phone>
      <email>Daniela.Hauenstein@usb.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Hendrik Scholl, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Princess Alexandra Hospital Nhs Foundation Trust</name>
      <address>
        <city>Harlow</city>
        <state>Essex</state>
        <zip>CM20 1QX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Naima Barbar</last_name>
      <email>n.babar@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Nikki White</last_name>
      <email>nikki.staines@nhs.net</email>
    </contact_backup>
    <investigator>
      <last_name>Priya Prakash, FRCOphth</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Southampton</name>
      <address>
        <city>Southampton</city>
        <state>Hampshire</state>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magdalena Ansari, Ms</last_name>
      <phone>023 8120 4606</phone>
      <phone_ext>4606</phone_ext>
      <email>Magdalena.Ansari@uhs.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Isabel Nica, Ms</last_name>
      <phone>023 8120 4606</phone>
      <phone_ext>4606</phone_ext>
      <email>Isabel.Nica@uhs.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Andrew J Lotery, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Mary's Hospital</name>
      <address>
        <city>Newport</city>
        <state>Isle Of Wight</state>
        <zip>PO30 5TG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sarah Hinch</last_name>
      <email>sarah.hinch@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Sarah Knight</last_name>
      <email>sarah.knight34@nhs.net</email>
    </contact_backup>
    <investigator>
      <last_name>Javeed Khan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>John Radcliffe Hospital</name>
      <address>
        <city>Oxford</city>
        <state>Oxfordshire</state>
        <zip>OX3 9DU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Buttress</last_name>
      <phone>01865 234729</phone>
      <email>daniel.buttress@ouh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Susan Downes</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Frimley Health Nhs Foundation Trust</name>
      <address>
        <city>Frimley</city>
        <state>Surrey</state>
        <zip>GU16 7UJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abigail Raguro</last_name>
      <phone>01276526982</phone>
      <email>a.raguro@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Geeta Menon, FRCOphth</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Salisbury Nhs Foundation Trust</name>
      <address>
        <city>Salisbury</city>
        <state>Wiltshire</state>
        <zip>SP2 8BJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louise Bell</last_name>
      <phone>01722 425026</phone>
      <phone_ext>2026</phone_ext>
      <email>lbell1@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Rashi Arora, FRCOphth</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospitals Bristol Nhs Foundation Trust</name>
      <address>
        <city>Bristol</city>
        <zip>BS1 3NU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eleanor Hiscott</last_name>
      <email>Eleanor.Hiscott@UHBristol.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Clare Bailey, FRCOphth</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moorfields Eye Hospital</name>
      <address>
        <city>London</city>
        <zip>EC1V 2PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivien Quan, Ms</last_name>
      <phone>0207 566 2109</phone>
      <email>Vivien.Quan@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Sobha Sivaprasad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Guy'S and St Thomas' Nhs Ft</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abigail Orr</last_name>
      <phone>020 718 84885</phone>
      <email>Abigail.Orr@gstt.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Samantha Mann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St Mary's Hospital, Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <zip>W2 1NY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Bonetti</last_name>
      <email>jessica.bonetti@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Saad Younis</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.uhs.nhs.uk/ClinicalResearchinSouthampton/Public-and-patients/Opt-out-of-research.aspx</url>
    <description>Research opt out process for PINNACLE</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 11, 2020</study_first_submitted>
  <study_first_submitted_qc>February 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 13, 2020</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Information can be made available on application to the Trial Management Group.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

